A17.82 Tuberculous meningoencephalitis

Name of the Condition

• Tuberculous meningoencephalitis

Summary

Tuberculous meningoencephalitis is a severe form of tuberculosis (TB) affecting the central nervous system, involving both the meninges (protective membranes around the brain and spinal cord) and the brain parenchyma. It is caused by Mycobacterium tuberculosis infection, leading to inflammation, neurological dysfunction, and potential long-term complications. Prompt diagnosis and treatment are critical to reduce morbidity and mortality.

Causes

Tuberculous meningoencephalitis results from the spread of Mycobacterium tuberculosis from a primary infection, typically in the lungs, to the central nervous system. The bacteria reach the meninges and brain through the bloodstream or by direct extension from adjacent infected tissues. The infection triggers an inflammatory response, causing damage to neural tissue and meninges.

Risk Factors

• Active pulmonary tuberculosis or other extrapulmonary TB
• Weakened immune system (e.g., HIV/AIDS, immunosuppressive therapy)
• Malnutrition or chronic illness
• Recent TB exposure or infection
• Lack of access to TB treatment or preventive care

Symptoms

• Persistent headache
• Fever and night sweats
• Stiff neck (meningitis)
• Nausea and vomiting
• Neurological deficits (e.g., weakness, numbness, confusion)
• Seizures
• Changes in mental status
• Altered consciousness

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging (e.g., MRI or CT scans), and laboratory testing. Cerebrospinal fluid (CSF) analysis is key, with findings such as elevated protein, low glucose, and lymphocytic pleocytosis. Acid-fast bacilli (AFB) smears or PCR testing of CSF may confirm Mycobacterium tuberculosis presence. Imaging helps identify meningeal inflammation or brain involvement.

Treatment Options

Treatment includes a prolonged course of anti-tubercular medications, typically lasting 9–12 months. Standard regimens combine multiple drugs (e.g., isoniazid, rifampin, pyrazinamide, ethambutol) to prevent resistance. Corticosteroids may be used to reduce inflammation and neurological damage. Adjunctive therapies address symptoms like seizures or increased intracranial pressure.

Prognosis and Follow-Up

Prognosis depends on early diagnosis, treatment adherence, and immune status. Delayed treatment increases the risk of severe neurological sequelae or death. Follow-up includes monitoring for treatment response, drug toxicity, and neurological recovery. Lifelong surveillance may be necessary for complications like hydrocephalus or cognitive impairment.

Complications

• Hydrocephalus (fluid buildup in the brain)
• Cerebral infarction or stroke
• Seizure disorders
• Cognitive impairment or dementia
• Permanent neurological deficits (e.g., paralysis, vision loss)
• Death (in severe or untreated cases)

Lifestyle & Prevention

• Complete the full course of prescribed anti-TB medications to prevent relapse or resistance.
• Maintain good nutrition and overall health to support immune function.
• Avoid exposure to active TB cases, especially in high-risk settings.
• Ensure timely treatment of latent TB infection to reduce progression to active disease.

When to Seek Professional Help

Seek immediate medical attention if experiencing:

• Sudden severe headache or neck stiffness
• Confusion, seizures, or loss of consciousness
• Persistent fever or worsening neurological symptoms
• Symptoms of increased intracranial pressure (e.g., vomiting, blurred vision)

Tips for Medical Coders

Code A17.82 is specific to tuberculous meningoencephalitis, a combination of meningitis and encephalitis due to TB. Document clinical findings (e.g., CSF analysis, imaging results) to confirm the diagnosis. Ensure differentiation from other CNS infections or TB manifestations (e.g., tuberculoma, isolated meningitis) to assign the correct code.